Completed PHASE4 INTERVENTIONAL 2-arm NCT00606242

Dose Response Effects of Inhaled Fluticasone on Airway Effects of Hypertonic-saline in Asthma (FluSAL)

A Randomized Double Blind Study of the Dose Response Effects of Fluticasone Propionate on Hypertonic-saline Induced Bronchoconstriction in Asthmatic Subjects

Sponsor: GlaxoSmithKline

Conditions Asthma

Interventions Fluticasone

Updated 6 times since 2017 Last updated: Mar 6, 2014 Started: Jan 31, 2000 Primary completion: Dec 31, 2002 Completion: Dec 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00606242, this PHASE4 trial focuses on Asthma and remains completed. Sponsored by GlaxoSmithKline, it has been updated 6 times since 2000, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Jan 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
National Heart, Lung, and Blood Institute (NHLBI)
University of California, San Francisco

Data source: University of California, San Francisco

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• San Francisco, United States